Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|RPTR-168||RPTR168|RPTR 168||RPTR-168 are autologous T lymphocytes that are targeted against multiple tumor associated antigens (TAAs) and attached to the interleukin IL-12, which bind to tumor cells expressing the TAAs, potentially leading to cytotoxic T-cell mediated killing of these cells and the activation of the anti-tumor immune response (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04762225||Phase I||RPTR-168||RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors (HNSCC, Cervical) and Melanoma||Recruiting||USA||0|